v3.8.0.1
Condensed Consolidated Balance Sheets - USD ($)
Apr. 30, 2018
Jul. 31, 2017
Current assets    
Cash and cash equivalents $ 10,118,965 $ 11,444,676
Prepaid expenses and other current assets 2,134,059 1,068,947
Investment securities 20,165,100
Total Current Assets 32,418,124 12,513,623
Investment securities 2,975,524
Property and equipment, net 1,295,669 2,410,099
Other long-term assets 369,833 309,187
Total Assets 37,059,150 15,232,909
Current liabilities    
Accounts payable and accrued liabilities 2,835,496 3,281,133
Accrued compensation 360,341 114,841
Total Current Liabilities 3,195,837 3,395,974
Other long-term liabilities 1,160,094 1,140,953
Total Liabilities 4,355,931 4,536,927
Commitments and Contingencies
Stockholders' Equity    
Common stock authorized - 160,000,000 common shares with a par value of $0.0001, common stock issued and outstanding - 51,892,734 and 21,618,194 common shares as of April 30, 2018 and July 31, 2017, respectively 5,190 2,162
Additional paid-in capital 143,079,816 93,866,088
Warrants issued and outstanding - 8,958,059 and 9,044,740 warrants as of April 30, 2018 and July 31, 2017, respectively 11,271,327 11,775,807
Accumulated other comprehensive loss (11,553) (3,620)
Accumulated deficit (121,641,561) (94,944,455)
Total Stockholders' Equity 32,703,219 10,695,982
Total Liabilities and Stockholders' Equity $ 37,059,150 $ 15,232,909

Source

v3.8.0.1
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
3 Months Ended 9 Months Ended
Apr. 30, 2018
Apr. 30, 2017
Apr. 30, 2018
Apr. 30, 2017
Income Statement [Abstract]        
Revenue
Expenses:        
Research and development 4,153,228 2,656,073 10,561,314 8,638,423
General and administrative 5,138,942 2,015,859 12,943,077 7,111,785
Loss from operations (9,292,170) (4,671,932) (23,504,391) (15,750,208)
Other income (expense), net 91,217 110,960 148,731 199,732
Loss on disposal of property and equipment (859,600) (875,098)
Warrant inducement expense (2,465,396)
Loss before income taxes (10,060,553) (4,560,972) (26,696,154) (15,550,476)
Provision for income taxes 951 1,391
Net loss $ (10,060,553) $ (4,560,972) $ (26,697,105) $ (15,551,867)
Basic and diluted net loss per common share $ (0.20) $ (0.22) $ (0.75) $ (0.79)
Weighted average shares used in computing basic and diluted net loss per common share 50,872,503 20,704,393 35,806,689 19,809,739

Source

v3.8.0.1
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
9 Months Ended
Apr. 30, 2018
Apr. 30, 2017
Operating activities    
Net loss $ (26,697,105) $ (15,551,867)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 273,136 284,319
Loss on disposal of property and equipment 875,098
Warrant inducement expense 2,465,396
Amortization of (discount)/premium on investments (1,052)
Stock-based compensation 5,904,920 3,378,991
Common stock issued for services 1,443,650
Changes in operating assets and liabilities:    
Decrease in prepaid expenses and other current assets (898,296) (315,976)
Decrease in other long-term assets (52,575) (163,542)
Decrease in accounts payable and accrued liabilities (578,007) (579,068)
Increase (decrease) in accrued compensation 245,500 (74,690)
Increase in other long-term liabilities 19,141 309,424
Net cash used in operating activities (17,000,194) (12,712,409)
Investing activities    
Purchases of property and equipment (51,666) (9,578)
Purchase of investment securities (23,234,225)
Net cash used in investing activities (23,285,891) (9,578)
Financing activities    
Proceeds from issuance of common stock through ESPP 35,809
Proceeds from issuance of common stock and warrants 32,283,444 44,057
Payment of financing and offering costs (3,577,214)
Proceeds from exercise of options 226,285
Proceeds from exercise of inducement warrants 9,999,983 30,950
Net cash provided by financing activities 38,968,307 75,007
Effect of exchange rate changes on cash (7,933) 7,094
Net decrease in cash (1,325,711) (12,639,886)
Cash and cash equivalents, at beginning of period 11,444,676 28,746,224
Cash and cash equivalents, at end of period 10,118,965 16,106,338
Supplemental disclosure for cash flow information:    
Income taxes 951 1,391
Noncash investing and financing transaction:    
Noncash expiration of warrants $ 1,200,742 $ 1,479,274

Source